4-[1-(2-フルオロ-4-メシルフェニル)-1H-ピラゾロ[3,4-d]ピリミジン-4-イルオキシ]ピペリジン-1-カルボン酸イソプロピル

Apd-668

HCID 11705608CAS 832714-46-2

基本情報

標準SMILES: CC(C)OC(=O)N1CCC(Oc2ncnc3c2cnn3-c2ccc(S(C)(=O)=O)cc2F)CC1
InChIKey: XTRUQJBVQBUKSQ-UHFFFAOYSA-N
分子式: C21H24FN5O5S
平均分子量: 477.5 g/mol
単同位体質量: 477.14821809

概要

APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also avoid hypoglycemia.

名称と識別子

優先名称: Apd-668
IUPAC: propan-2-yl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[5,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate
現地名: 4-[1-(2-フルオロ-4-メシルフェニル)-1H-ピラゾロ[3,4-d]ピリミジン-4-イルオキシ]ピペリジン-1-カルボン酸イソプロピル
英語名: APD668
分子式: C21H24FN5O5S
分子量: 477.51

名称と別名

APD668832714-46-2APD-668JNJ-28630368JC77BCH2APRefChem:113299Isopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)piperidine-1-carboxylateMFCD12032117isopropyl 4-(1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)piperidine-1-carboxylateCHEMBL1775179propan-2-yl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylateisopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)piperidine-1-carboxylate .

名称をさらに表示

プロパン-2-イル 4-{[1-(2-フルオロ-4-メタンスルホニルフェニル)-1H-ピラゾロ[3,4-d]ピリミジン-4-イル]オキシ}ピペリジン-1-カルボキシラート4-[1-(2-フルオロ-4-メシルフェニル)-1H-ピラゾロ[3,4-d]ピリミジン-4-イルオキシ]ピペリジン-1-カルボン酸イソプロピルCS-1179APD 668, >=98%APD 668APD668, 10 mM in DMSOisopropyl 4-(1-(2-fluorine-4-(carbosulfonyl)phenyl)-1H-pyrazolo[3,4-D]pyrimidine-4-oxy)piperidine-1-carboxylate4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester1-Piperidinecarboxylic acid,4-[[1-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]-, 1-methylethyl esterInhibitor,CYPs,APD668,diabetes,Cytochrome P450,APD-668,GPR119,Potassium Channel,coupled,G-protein,steatohepatitis,CYP2C9,G Protein-Coupled Receptor 119,inhibit,KcsAisopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)piperidine-1-carboxylate APD668

ISOPROPYL 4-{[1-(2-FLUORO-4-METHANESULFONYLPHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]OXY}PIPERIDINE-1-CARBOXYLATEpropan-2-yl 4-{[1-(2-fluoro-4-methanesulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidine-1-carboxylate1-Methylethyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)-1-piperidinecarboxylate1-Piperidinecarboxylic acid, 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)-, 1-methylethyl ester4-((1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)piperidine-1-carboxylic acid isopropyl esterIsopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)-1-piperidinecarboxylatePropan-2-yl 4-(1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo(4,5-E)pyrimidin-4-yl)oxypiperidine-1-carboxylatepropan-2-yl 4-[1-(2-fluoranyl-4-methylsulfonyl-phenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate

データベース識別子

CAS: 832714-46-2
PubChem CID: 11705608
DTXSID: DTXSID701025686
ChEMBL: CHEMBL1775179
UNII: JC77BCH2AP
Nikkaji: J3.130.251J

物性

構造計算による物性

XLogP: 2.7
極性表面積: 125 Å²
水素結合供与体数: 0
水素結合受容体数: 9
回転可能結合数: 6
重原子数: 33
形式電荷: 0
複雑度: 788

実験および物理化学的性質

LogP3.0

物理化学的性質

沸点: 611.6 · 611.6±55.0 °C(Predicted)
比重(密度): 1.47 · 1.47±0.1 g/cm3(Predicted)
貯蔵温度: -20 °C · Store at -20°C
溶解性: 2 O; · insoluble in H2O; ≥17.4 mg/mL in DMSO; ≥2.61 mg/mL in EtOH with gentle warming and ultrasonic
外見: solid
酸解離定数(Pka): 2.13 · 2.13±0.30(Predicted)
色: White to off-white

安全と法規制

安全データ

危険有害性情報: コード危険有害性情報危険有害性クラス区分注意喚起語シンボル P コード H315

化学と産業

薬理情報

Mechanism of Action · 1 件

The GDIR mechanism is glucose dependent: in preclinical studies, GDIR agonists only lowered blood glucose when it rose above normal levels, such as after a meal. Therefore, unlike the glucose-insensitive sulfonylureas, Arena's GDIR agonists are not expected to lower normal fasting blood glucose levels or cause hypoglycemia. In addition, GDIR stimulation has been found to increase the levels and activity of intracellular factors thought to be involved in the preservation of beta cells.